Teva Airduo ® Digihaler ™ inhaling powder gets FDA approval

recently,pharmaceutical(http://giant Teva announced that the U.SFood andDrug(http://Authority (
(http://) has approved airduo® Digihaler ™ (fluoroaticaso, 113 mcg/14 mcg) inhaled powder, which can be connected to a companion mobile app to provide information on the use of inhalers for asthma patientsAirduo® Digihaler ™ is the first digital-maintained asthma inhaler therapy with integrated sensors for
people 12 years and older with(http://not suitable for relieving sudden breathing problems or replacing rescue inhalersAbout Airduo® The airduo™
the Airduo® the ™ ™ the sensor, can detect when (http:// use the inhaler and measure the suction speed The data is then sent to a companion mobile app using Bluetooth wireless technology so that patients can view their treatment data at any time and share it with their medical (http:// health care provider if needed Patients can also arrange reminders on their smartphones and use Airduo ® Digihaler ™ treatment as required 　　The approval of Airduo® Digihaler ™ is based on the review of the supplementary New Drug (http:// Application (sNDA) submitted to the FDA by Tyva Airduo® Digihaler ™ combines a breath-driven multi-dose dry powder inhaler with fluoroteocason of propylene acid," in which fluorococinacinis is an inhaling corticosteroid (ICS) that helps reduce inflammation in the lungs, and Sametero is a long-acting beta-2 epinephrine-boosting (LABA) that helps the muscles around the airways of the lungs relax to prevent symptoms 　　Airduo ® Digihaler ™ approved for low, medium and high doses: 55/14 mcg, 113/14 mcg, 232/14 mcg, twice a day 　　As a fixed-dose combination asthma therapy with ICS and LABA, Airduo ® Digihaler ™ contain the same active ingredient as a dvair diskus ®, which is approved for low, medium and high doses: 100/50 mcg, 250/50 mcg, 500/50 mcg